NCT01831947已完成4 期
Efficacy of Ranibizumab Treatment Every 2 Month Compared to Treatment on Demand on Patients With Choroidal Neo-vascularization (CNV) as a Consequence of Age-related Macular Degeneration (AMD)
Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2010年4月1日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
- 试验地点
- 2
- 主要终点
- best-corrected visual acuity
研究概览
简要总结
This clinical trial investigates the impact of intravitreal injection of Ranibizumab antibody on the acuteness of vision. Patients included are suffering from choroidal neo-vascularization (CNV) as a consequence of age-related macular degeneration (AMD).
Initially, all patients get injections of 0.5 mg Ranibizumab in monthly intervals for 3 months. Subsequently, one group gets Ranibizumab in intervals of 2 months, whereas a second group is treated on demand.
The primary end point of the study is the change of best-corrected visual acuity after 12 month.
Secondary end points include the impact of Ranibizumab on morphological changes of the retina, the number of patients with gain or loss of 15 or more letters visual acuity after 12 months, changes in quality of life and the number of injections required during the first 12 months of treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients with choroidal neo-vascularization (CNV) as a consequence of age-related macular degeneration (AMD)
- •age 50 and older, male and female
- •membrane <= 12 papillary diameter
- •visual acuity between 20/320 and 20/40 (ETDRS)
- •written informed consent
排除标准
- •known hypersensitivity to the medicinal product under investigation, ingredients or medicinal products with a similar chemical structure
- •participation in another clinical trial within the last 4 weeks
- •unability to understand trial information
- •pregnant or lactating women
- •women with an amenorrhea < 12 months
- •suspected unability to cooperate
- •detachment of pigment epithelium without membrane detection >= 50%,retinal angiomatotic proliferation (RAP), presumed ocular histoplasmosis syndrome (POHS), chorioretinal anastomosis (CRA), myopic CNV, CNV following trauma, uveitis, RCS or reasons except AMD
- •rupture of pigment epithelium
- •sub-retinal bleeding >= 50% of membrane or >= 1 PD
- •sub-retinal fibrosis or chorio-atrophy
- •pre-treatment with Verteporfin (photodynamic therapy), radiotherapy, trans-pupillary thermotherapy of the eye under investigation as a consequence of maculadegeneration treatment with Verteporfin of the eye not under investigation within 7 days prior inclusion
- •former participation in clinical trials with anti-angiogenic substances: Pegaptanib, Ranibizumab, Bevacizumab, Anecortave Acetat, Proteinkinase C Inhibitors
- •former injection of anti-angiogenic substances in the eye under investigation
- •former focal sub-foveal lasercoagulation of the eye under investigation
- •juxta- or extra-foveal lasercoagulation of the eye under investigation within 1 month prior inclusion
- •former vitrectomy
- •former surgery as a consequence of maculadegeneration
- •glaucoma patients which have been treated with prostaglandin containing eye drops
- •other ocular diseases which may lead to surgery within the clinical study or may lead to a loss of vision of two lines
- •acute intraocular inflammation of the eye under investigation
- •vitreous hemorrhage of the eye under investigation
- •macula-foramen of the eye under investigation
- •diabetic retinopathy
- •former retina detachment of the eye under investigation
- •acute conjunctivitis, keratitis, scleritis, or endophthalmitis
- •aphakia or pseudo-aphakia with damaged back-capsule(exception: YAG-capsulotomy)
- •myopia larger than -8 diopter
- •former intra-ocular surgery of the eye under investigation within 2 months prior inclusion
- •de-compensated glaucoma with >= 30 mm Hg despite therapy
- •former filtrating glaucoma surgery of the eye under investigation
- •former corneal grafting of the eye under investigation
- •former stroke or heart attack
- •on-going therapy because of systemic infection
- •known allergic reaction to fluorescein
- •bad quality of fundus documentation because of bad range of vision
结局指标
主要结局
best-corrected visual acuity
时间窗: 12 months after start of treatment
Change of best-corrected visual acuity before and 12 months after start of treatment with respect to number of letters read on ETDRS-sheets (Early Treatment Diabetes Retinopathy Study Sheets).
次要结局
- Fluoresceinangiography(12 months after start of treatment)
- Photography(12 months after treatment start)
- optical coherence tomography (OCT)(12 months after treatment start)
- number of injections(12 months after treatment start)
- quality of life(12 months after treatment start)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)Proliferative Diabetic RetinopathyVitreous HemorrhageNCT00996437Jaeb Center for Health Research261
Unknown
不适用
Comparison of Intravitreal Ranibizumab and Macular Grid-pattern Laser for Treatment of Diabetic Macular EdemaMacular EdemaNCT00994799Szeged University50
已完成
3 期
To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular EdemaMacular Edema (ME)NCT01846299Novartis Pharmaceuticals181
已完成
2 期
Dosing Study of Ranibizumab for Diabetic Retinal and Macular EdemaMacular EdemaDiabetic RetinopathyNCT01476449Retina Vitreous Associates of Florida20
Unknown
2 期
Safety and Efficacy of Intravitreal Ranibizumab as a Preoperative Adjunct Treatment Before Vitrectomy Surgery in Proliferative Diabetic Retinopathy (PDR) Compared to Vitrectomy AloneDiabetic RetinopathyNCT00931125Attila Vajas70